Vienna Challenge Chamber Study Using RV658 in Subjects With Allergic Rhinitis
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
RV568 is being developed for the treatment of diseases such as asthma, COPD and allergic
rhinitis (e.g. hayfever). The main aim of this study is to investigate whether RV568
ameliorates the nasal symptoms to low doses of grass pollen in healthy subjects with seasonal
allergic rhinitis.